Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Weight Management
Lilly's triple-agonist of GLP-1, GIP, and glucagon receptors — the strongest weight-loss data yet reported.
Peptide B
Weight Management
Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials.
Typical vial
10 mg
Typical dose
500-12000 mcg
Half-life
~6 days (~144 hours)
FDA status
Not FDA approved. In Phase 3 clinical trials (TRIUMPH progra…
Typical vial
10 mg
Typical dose
300-6000 mcg
Half-life
~80-90 hours (once-weekly dosing)
FDA status
Not FDA approved. Investigational compound in phase 3 clinic…
Retatrutide effects
Survodutide effects
Retatrutide side effects
Survodutide side effects
Retatrutide dosing ranges
Obesity / weight loss (Phase 2 / 3 protocol)
1-12 mg · Once weekly (SubQ), dose-titrated · Long-term per clinical protocol
Self-experimentation (no clinical guidance)
0.5 mg start, titrate to tolerance · Once weekly · Long-term with careful titration
Survodutide dosing ranges
Obesity (phase 2/3 protocol)
0.3-6.0 mg · Once weekly SubQ (titrated) · Long-term (chronic dosing)
MASH / NASH (phase 2)
1.2-6.0 mg · Once weekly SubQ (titrated) · 48 weeks minimum
Type 2 diabetes (phase 2)
0.3-4.8 mg · Once weekly SubQ · Long-term
Retatrutide: Lilly's triple-agonist of GLP-1, GIP, and glucagon receptors — the strongest weight-loss data yet reported. Typical dose 500-12000 mcg. Survodutide: Dual GLP-1 / glucagon receptor agonist in late-stage obesity trials. Typical dose 300-6000 mcg. Both fall under the Weight Management category.
Stacking Retatrutide with Survodutide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
Retatrutide is typically dosed: Once weekly (SubQ), dose-titrated for Obesity / weight loss (Phase 2 / 3 protocol); Once weekly for Self-experimentation (no clinical guidance). Survodutide is typically dosed: Once weekly SubQ (titrated) for Obesity (phase 2/3 protocol); Once weekly SubQ (titrated) for MASH / NASH (phase 2); Once weekly SubQ for Type 2 diabetes (phase 2).
Retatrutide: Not FDA approved. In Phase 3 clinical trials (TRIUMPH program for obesity, SYNERGY-NASH for MASH). FDA submission anticipated 2026-2027 pending Phase 3 readouts. Survodutide: Not FDA approved. Investigational compound in phase 3 clinical trials for obesity and MASH/NASH.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free